ReVision Optics, Inc., a Lake Forest, California company, is reporting the infusion of $25 million in a Series D financing from three venture capital firms to further the development and market introduction of its implantable device to correct presbyopia.
The following details about its removable and adjustable device are provided by the company:
The PRESBYLENS™ Corneal Inlay (CI) is designed to correct presbyopia by changing the shape of the eye’s corneal surface.
The PRESBYLENS™ CI is similar in nature to a soft contact lens; however the PRESBYLENS&tradel CI is inserted just under the eye’s outer surface.
The PRESBYLENS™ CI is a mere 1.5 mm in diameter and it is ultra thin (approximately half the thickness of a sheet of paper); these dimensional factors as well as the proprietary bioengineering of the material are intended to make the PRESBYLENS™ CI biocompatible within the cornea.
Three-fourths (3/4) of your eyes focusing power (refractive power) comes from the cornea; the outermost tissue of the eye. The unique properties of the cornea and the optical difference between the cornea and air (corneal/air interface) allow for very small changes in the surface of the cornea to have large effects on the eye’s focusing power.
These optical characteristics of the cornea are essentially why LASIK works; LASIK removes a small portion of the corneal tissue to change the surface of the cornea and improve your vision.
Similarly, the PRESBYLENS™ Corneal Inlay (CI) is also designed to take advantage of the cornea’s optical properties, but by adding a small inlay just under the surface of the cornea. Once the 1.5 mm corneal inlay is inserted, it is designed to change only a small central area of the cornea to increase near focusing power with little decrease in intermediate and distance focusing as the figure above illustrates.
ReVision Optics’ website…
More from Red Herring: An Eye for a Deal
Press release: ReVision Optics, Inc. Raises $25M in Series D Financing …